Cited by 1,133COVID-19 Clinical Research StudiesRenin-Angiotensin System StudiesCOVID-19 and healthcare impacts

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Open access

Zhang, Peng, Zhu, Lihua, Cai, Jingjing, Lei, Fang, Qin, Juan-Juan, Xie, Jing, Liu, Ye-Mao, Zhao, Yan-Ci, Huang, Xuewei, Lin, Lijin, Xia, Meng, Chen, Ming-Ming, Cheng, Xu, Zhang, Xiao, Guo, Deliang, Peng, Yuanyuan, Ji, Yan-Xiao, Chen, Jing, She, Zhi-Gang, Wang, Yibin, Xu, Qingbo, Tan, Renfu, Wang, Haitao, Lin, Jun, Luo, Pengcheng, Fu, Shouzhi, Cai, Hongbin, Ye, Ping, Xiao, Bing, Mao, Weiming, Liu, Liming, Yan, Youqin, Liu, Mingyu, Chen, Manhua, Zhang, Xiao-Jing, Wang, Xinghuan, Touyz, Rhian M., Xia, Jiahong, Zhang, Bing-Hong, Huang, Xiaodong, Yuan, Yufeng, Loomba, Rohit, Liu, Peter P., Li, Hongliang·2020·Circulation Research

DOI 10.1161/circresaha.120.317134PMC PMC7265882

Open this paper in CoChat — free account Open PDF

Abstract

Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. Objective: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19. Methods and Results: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55–68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57–69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19–0.92]; P =0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15–0.89]; P =0.03). Further subgroup propensity score-matched analysis indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12–0.70]; P =0.01) in patients with COVID-19 and coexisting hypertension. Conclusions: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circresaha.120.317134

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figure 1. The flowchart showing the strategy of participant enrollment. a, 1128 participants with a history of hypertension enrolled in the hypertension cohort. b, 2302 participants without a history of hypertension enrolled in the nonhypertension cohort. c, 188 patients with hypertension who taking ACEI (angiotensin-converting enzyme inhibitor) or ARB (angiotensin II receptor blocker) during hospitalization were enrolled in the ACEI/ARB cohort. Patients discontinued treatment of hypertension due to inability to take medications or hypotension were not excluded from the cohort. d, 940 patients with hypertension who never taking ACEI and ARB during hospitalization were enrolled in the non-ACEI/ARB cohort. e, Propensity score-matched age, gender, cough, dyspnea, comorbidities (diabetes mellitus, coronary heart disease, and chronic renal disease), chest computerized tomography (CT)-diagnosed lung lesions, and incidence of increased CRP (C-reactive protein) and creatine. Hospital site as a random effect in the mixed-effect Cox model. f, 557 patients with antihypertension drug who never taking ACEI and ARB during hospitalization were enrolled in the secondary non-ACEI/ARB cohort. SARS-COV-2 indicates severe acute respiratory syndrome coronavirus 2.CC BY · PubMed Central

Figure 2. Kaplan-Meier curves for cumulative probability of Coronavirus disease 2019 (COVID-19) mortality during 28-day follow-up duration in ACEI (angiotensin-converting enzyme inhibitor)/ARB (angiotensin II receptor blocker) or non-ACEI/ARB cohort among 1128 patients with hypertension. The unmatched model and the median (interquartile range [IQR]) observation time was 28 (20–28) in ACEI/ARB cohort and 28 (19–28) in non-ACEI/ARB cohort (A). Propensity-score matched model and the median (IQR) observation time was 28 (20.5–28) in ACEI/ARB cohort and 28 (18–28) in non-ACEI/ARB cohort (B). The blips indicate censoring. HR indicates hazard ratio.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citation
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Self-citation
Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citation
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Self-citation
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,745
Sensitivity analysis in observational research: Introducing the E-value
VanderWeele, T. J., & Ding, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2607 · Cited by 6,350
Notice
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.1 · Cited by 4,326
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Self-citation

Show all 32 references

Sorted by citations

Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
Zhu, L., She, Z., Cheng, X., Qin, J., Zhang, X.-J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.021 · Cited by 1,638
Self-citation
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453
Postmortem examination of COVID‐19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction
Menter, T., Haslbauer, J. D., Nienhold, R., Savic, S., Hopfer, H., Deigendesch, N., Frank, S., Turek, D., Willi, N., Pargger, H., et al. (2020) · Histopathology · doi:10.1111/his.14134 · Cited by 1,239
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., Hou, C., Wang, H., Liu, J., Yang, D., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03120-0 · Cited by 1,175
Self-citation
Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A. K., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,167
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection
Diao, B., Wang, C., Wang, R., Feng, Z., Zhang, J., Yang, H., Tan, Y., Wang, H., Wang, C., Liu, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22781-1 · Cited by 924
Self-citation
Collider bias undermines our understanding of COVID-19 disease risk and severity
Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19478-2 · Cited by 826
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review
Izcovich, A., Ragusa, M. A., Tortosa, F. G., Marzio, M. A. L., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241955 · Cited by 676
Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 610
Self-citation
Acute kidney injury in critically ill patients with COVID-19
Gabarre, P., Dumas, G., Dupont, T., Darmon, M., Azoulay, É., & Zafrani, L. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06153-9 · Cited by 541
Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
Bhaskar, S. M. M., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 524
In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
Zhang, X.-J., Qin, J., Cheng, X., Shen, L., Zhao, Y.-C., Yuan, Y., Lei, F., Chen, M.-M., Yang, H., Bai, L., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.015 · Cited by 476
Self-citation
Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies
Xu, S., Ilyas, I., & Weng, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 483
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China
Lei, F., Liu, Y.-M., Zhou, F., Qin, J., Zhang, P., Zhu, L., Zhang, X., Cai, J., Lin, L., Ouyang, S., et al. (2020) · Hepatology · doi:10.1002/hep.31301 · Cited by 434
Self-citation
A Global Review on Short Peptides: Frontiers and Perspectives
Apostolopoulos, V., Bojarska, J., Chai, T., Elnagdy, S. M., Kaczmarek, K., Matsoukas, J., New, R. R. C., Parang, K., Paredes‐López, O., Parhiz, H., et al. (2021) · Molecules · doi:10.3390/molecules26020430 · Cited by 459
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
Gao, C., Cai, Y., Zhang, K., Zhou, L., Zhang, Y., Zhang, X., Li, Q., Li, W., Yang, S., Zhao, X., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa433 · Cited by 421
Self-citation
Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis
de Almeida-Pititto, B., Dualib, P. M., Zajdenverg, L., Dantas, J. R., de Souza, F. D., Rodacki, M., Bertoluci, M. C., & Brazilian Diabetes Society Study Group (SBD) (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00586-4 · Cited by 391
Age and Multimorbidity Predict Death Among COVID-19 Patients
Iaccarino, G., Grassi, G. M., Borghi, C., Ferri, C., Salvetti, M., Volpe, M., Cicero, A. F. G., Minuz, P., Muiesan, M. L., Mulatero, P., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15324 · Cited by 404
Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID‐19 patients in Michigan, United States
Imam, Z., Odish, F., Gill, I., O’Connor, D., Armstrong, J., Vanood, A., Ibironke, O., Hanna, A., Ranski, A., & Halalau, A. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13119 · Cited by 369
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Lópes, R. D., Macedo, A. V. S., Silva, P. G. M. D. B. E., Moll-Bernardes, R. J., dos Santos, T. M., Barbosa, L. M., Feldman, A., Arruda, G., de Albuquerque, D. C., Camiletti, A. S., et al. (2021) · JAMA · doi:10.1001/jama.2020.25864 · Cited by 374
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
Hippisley‐Cox, J., Young, D., Coupland, C. A. C., Channon, K. M., Tan, P. S., Harrison, D. A., Rowan, K., Aveyard, P. N., Pavord, I. D., & Watkinson, P. (2020) · Heart · doi:10.1136/heartjnl-2020-317393 · Cited by 359
Heart Failure in COVID-19 Patients: Prevalence, Incidence and Prognostic Implications
Rey, J. R., Caro‐Codón, J., Rosillo, S. O., Iniesta, Á. M., Castrejón‐Castrejón, S., Clement, I. M., Martín‐Polo, L., Argos, C. M., Rodríguez‐Sotelo, L., García‐Veas, J. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1990 · Cited by 321
Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis
Ng, W. H., Tipih, T., Aminake, M. N., Vermeulen, J., Goedhals, D., Sempa, J. B., Burt, F. J., Taylor, A., & Mahalingam, S. (2021) · mBio · doi:10.1128/mbio.03647-20 · Cited by 296
Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor
Al-Karmalawy, A. A., Dahab, M. A., Metwaly, A. M., Elhady, S. S., Elkaeed, E. B., Eissa, I. H., & Darwish, K. M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.661230 · Cited by 294
The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries
Román, G. C., Spencer, P. S., Reis, J. J., Buguet, A., Faris, M. E. A., Katrak, S. M., Láinez, M. J. A., Medina, M. T., Meshram, C., Mizusawa, H., et al. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116884 · Cited by 286
COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up
Tajbakhsh, A., Hayat, S. M. G., Taghizadeh, H., Akbari, A., inabadi, M., Savardashtaki, A., Johnston, T. P., & Sahebkar, A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1822737 · Cited by 290
p38 MAPK inhibition: A promising therapeutic approach for COVID-19
Grimes, J. M., & Grimes, K. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.05.007 · Cited by 259
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy
Datta, P. K., Liu, F., Fischer, T., Rappaport, J., & Qin, X. (2020) · Theranostics · doi:10.7150/thno.48076 · Cited by 262
COVID-19 and metabolic disease: mechanisms and clinical management
Steenblock, C., Schwarz, P. E. H., Ludwig, B., Linkermann, A., Zimmet, P., Kulebyakin, K. Y., Va, T., Markov, A. G., Lehnert, H., de Angelis, M. H., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00244-8 · Cited by 256
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3
Mikuls, T. R., Johnson, S. R., Fraenkel, L., Arasaratnam, R. J., Baden, L. R., Bermas, B. L., Chatham, W. W., Cohen, S. B., Costenbader, K. H., Gravallese, E. M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41596 · Cited by 242
COVID-19 and Heart Failure: From Infection to Inflammation and Angiotensin II Stimulation. Searching for Evidence from a New Disease
Tomasoni, D., Italia, L., Adamo, M., Inciardi, R. M., Lombardi, C., Solomon, S. D., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1871 · Cited by 236
Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis
Corona, G., Pizzocaro, A., Vena, W., Rastrelli, G., Semeraro, F. F., Isidori, A. M., Pivonello, R., Salonia, A., Sforza, A., & Maggi, M. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09630-8 · Cited by 233
Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights
Divani, A. A., Andalib, S., Napoli, M. D., Lattanzi, S., Hussain, M. S., Biller, J., McCullough, L. D., Azarpazhooh, M. R., Seletska, A., Mayer, S. A., et al. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.104941 · Cited by 236
Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers are Not Associated with Severe COVID-19 Infection in a Multi-Site UK Acute Hospital Trust
Bean, D. M., Kraljević, Ž., Searle, T., Bendayan, R., O’Gallagher, K., Pickles, A. R., Folarin, A., Roguski, Ł., Noor, K., Shek, A., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1924 · Cited by 231
COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study
Huang, S., Wang, J., Liu, F., Liu, J., Cao, G., Yang, C., Liu, W. Y., Tu, C., Zhu, M., & Xiong, B. (2020) · Hypertension Research · doi:10.1038/s41440-020-0485-2 · Cited by 227
Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence
Treskova, M., Haas, L., Reda, S. A., Pilic, A., Borodova, A., Karimi, K., Koch, J., Nygren, T. M., Scholz, S. M., Schönfeld, V., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02058-6 · Cited by 219
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
for the European Society for Blood and Marrow Transplantation, Ljungman, P. T., Mikulska, M., de la Cámara, R., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R. F., Dolstra, H., Lankester, A. C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0919-0 · Cited by 217
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1
Mikuls, T. R., Johnson, S. R., Fraenkel, L., Arasaratnam, R. J., Baden, L. R., Bermas, B. L., Chatham, W., Cohen, S. B., Costenbader, K. H., Gravallese, E. M., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41301 · Cited by 213
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Landstra, C. P., & de Koning, E. J. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649525 · Cited by 226
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions
Butler, D., Mozsary, C., Meydan, C., Foox, J., Rosiene, J. A., Shaiber, A., Danko, D., Afshinnekoo, E., MacKay, M. J., Sedlazeck, F. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21361-7 · Cited by 200
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
Bernard, I., Limonta, D., Mahal, L. K., & Hobman, T. C. (2020) · Viruses · doi:10.3390/v13010029 · Cited by 187
Diabetes and COVID-19: evidence, current status and unanswered research questions
Gupta, R., Hussain, A., & Misra, A. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0652-1 · Cited by 183
Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor
Davidson, A. M., Wysocki, J. A., & BATLLE, D. C. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15256 · Cited by 183
A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180
Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis*
Karakike, E., Giamarellos‐Bourboulis, E. J., Kyprianou, M., Fleischmann-Struzek, C., Pletz, M. W., Netea, M. G., Reinhart, K., & Kyriazopoulou, E. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005195 · Cited by 188
Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Perrotta, F., Matera, M. G., Cazzola, M., & Bianco, A. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.105996 · Cited by 180
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic
Triggle, C. R., Bansal, D., Ding, H., Islam, M. M., Farag, E., Hadi, H. A., & Sultan, A. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.631139 · Cited by 187
ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis
Zhang, X., Yu, J., Pan, L., & Jiang, H.-Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104927 · Cited by 177
Self-citation
Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
Shibata, S., Arima, H., Asayama, K., Hoshide, S., Ichihara, A., Ishimitsu, T., Kario, K., Kishi, T., Mogi, M., Nishiyama, A., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-0515-0 · Cited by 181
COVID-19 y diabetes mellitus: una relación bidireccional
Lima-Martínez, M. M., Boada, C. C., Madera-Silva, M. D., Marín, W., & Contreras, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.10.001 · Cited by 206
Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies
Lopes‐Pacheco, M., Silva, P. L., Cruz, F. F., Battaglini, D., Robba, C., Pelosi, P. P., Morales, M. M., Neves, C. C., & Rocco, P. R. M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.593223 · Cited by 178
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
The Task Force for the management of COVID-19 of the European Society of Cardiology, Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A. L., Baumbach, A., Behr, E. R., Berti, S. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab697 · Cited by 177
Self-citation
Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19
Trump, S., Lukassen, S., Anker, M. S., Chua, R. L., Liebig, J., Thürmann, L., Corman, V. M., Binder, M., Loske, J., Klasa, C., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00796-1 · Cited by 173
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis
Narula, S., Yusuf, S., Chong, M., Ramasundarahettige, C. F., Rangarajan, S., Bangdiwala, S. I., van Eickels, M., Leineweber, K., Wu, A., Pigeyre, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31964-4 · Cited by 169
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
Spiegeleer, A. D., Bronselaer, A., Teo, J., Byttebier, G., Tré, G. D., Belmans, L., Dobson, R., Wynendaele, E., de Wiele, C. V., Vandaele, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2020.06.018 · Cited by 166
Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes
Cheng, X., Liu, Y.-M., Li, H., Zhang, X., Lei, F., Qin, J., Chen, Z., Deng, K., Lin, L., Chen, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.013 · Cited by 159
Self-citation
Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19
Qin, J., Cheng, X., Zhou, F., Lei, F., Akolkar, G., Cai, J., Zhang, X.-J., Blet, A., Xie, J., Zhang, P., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15528 · Cited by 152
Self-citation
COVID-19 Pandemic: Cardiovascular Complications and Future Implications
Bandyopadhyay, D., Akhtar, T., Hajra, A., Gupta, M., Das, A., Chakraborty, S., Pal, I., Patel, N., Amgai, B., Ghosh, R. K., et al. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00420-2 · Cited by 149
Challenges for Drug Repurposing in the COVID-19 Pandemic Era
Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., & Trifirò, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588654 · Cited by 156
COVID-19 and its cardiovascular effects: a systematic review of prevalence studies
Pellicori, P., Doolub, G., Wong, C. M., Lee, K. S., Mangion, K., Ahmad, M., Berry, C., Squire, I. B., Lambiase, P. D., Lyon, A. R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013879 · Cited by 151
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis
The Task Force for the management of COVID-19 of the European Society of Cardiology, Baigent, C., Windecker, S., Andreini, D., Arbelo, E., Barbato, E., Bartorelli, A. L., Baumbach, A., Behr, E. R., Berti, S. L., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab696 · Cited by 147
Self-citation
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports
Scheen, A. J., Marre, M., & Thivolet, C. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.008 · Cited by 145
Role of Hypertension on the Severity of COVID-19: A Review
Peng, M., He, J., Xue, Y., Xue, Y., Liu, S., & Gong, Z. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001116 · Cited by 147
Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence
Sriram, K., & Insel, P. A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1863 · Cited by 142
Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial
Lópes, R. D., Macedo, A. V. S., Silva, P. G. M. D. B. E., Moll-Bernardes, R. J., Feldman, A., Arruda, G., de Souza, A. S., de Albuquerque, D. C., Barbosa, L. M., Santos, M. F., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.05.002 · Cited by 138
Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis
Morales, D. R., Conover, M. M., You, S. C., Pratt, N. L., Kostka, K., Duarte‐Salles, T., Fernández‐Bertolín, S., Aragón, M., DuVall, S. L., Lynch, K. E., et al. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30289-2 · Cited by 138
Response by Zhang et al to Letter Regarding Article, “Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19”
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J., Wang, Y., Yuan, Y., Loomba, R. S., Liu, P. P., & Li, H. (2020) · Circulation Research · doi:10.1161/circresaha.120.317242 · Cited by 136
Self-citation
The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies
Albini, A., Guardo, G. D., Noonan, D. M., & Lombardo, M. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02364-6 · Cited by 138
SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications
Groß, S., Jahn, C., Cushman, S., Bär, C., & Thum, T. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.04.031 · Cited by 134
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
Chung, M. K., Karnik, S. S., Saef, J., Bergmann, C. C., Barnard, J., Lederman, M. M., Tilton, J. C., Cheng, F., Harding, C. V., Young, J. B., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102907 · Cited by 138
Approach to Acute Cardiovascular Complications in COVID-19 Infection
Ranard, L. S., Fried, J., Abdalla, M., Anstey, D. E., Givens, R. C., Kumaraiah, D., Kodali, S., Takeda, K., Karmpaliotis, D. I., Rabbani, L. E., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007220 · Cited by 133
Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020
Kaeuffer, C., Hyaric, C. L., Fabacher, T., Mootien, J., Dervieux, B., Ruch, Y., Hugerot, A., Zhu, Y.-J., Pointurier, V., Clère-Jehl, R., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.48.2000895 · Cited by 130
SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management
Wu, L., O’Kane, A., Hu, P., Bi, Y., Motriuk-Smith, D., & Ren, J. T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114114 · Cited by 132
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults
Mackey, K., King, V. J., Gurley, S. B., Kiefer, M., Liederbauer, E., Vela, K., Sonnen, P., & Kansagara, D. L. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1515 · Cited by 130
Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19
Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino, R. B., & Harrington, D. P. (2020) · New England Journal of Medicine · doi:10.1056/nejme2012924 · Cited by 126
Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China
Ran, J., Song, Y., Zhuang, Z., Han, L., Zhao, S., Cao, P., Geng, Y., Xu, L., Qin, J., He, D., et al. (2020) · Hypertension Research · doi:10.1038/s41440-020-00541-w · Cited by 132
Self-citation
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19
Baral, R., Tsampasian, V., Dębski, M., Moran, B., Garg, P., Clark, A., & Vassiliou, V. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3594 · Cited by 127
Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies
Mercurio, I., Tragni, V., Busto, F., Grassi, A., & Pierri, C. L. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03580-1 · Cited by 129
Kidney Function Indicators Predict Adverse Outcomes of COVID-19
Liu, Y.-M., Xie, J., Chen, M.-M., Zhang, X., Cheng, X., Li, H., Zhou, F., Qin, J.-J., Lei, F., Chen, Z., et al. (2020) · Med · doi:10.1016/j.medj.2020.09.001 · Cited by 122
Self-citation
Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID‐19—Mechanisms and Therapeutic Targets
Fodor, A., Tiperciuc, B., Login, C., Orasan, O. H., Lazăr, A.-L., Buchman, C., Hanghicel, P., Sitar-Tăut, A., Suharoschi, R., Vulturar, R., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/8671713 · Cited by 127
Are we equal in adversity? Does Covid-19 affect women and men differently?
Rozenberg, S., Vandromme, J., & Martin, C. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.05.009 · Cited by 123
Statins: Could an old friend help in the fight against COVID‐19?
Rodrigues-Díez, R. R., Tejera‐Muñoz, A., Márquez‐Expósito, L., Rayego‐Mateos, S., Santos‐Sanchez, L., Marchant, V. A., Tejedor-Santamaria, L., Ramos, A. M., Ortíz, A., Egido, J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15166 · Cited by 121
Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis
Fu, E. L., Janse, R. J., de Jong, Y., van der Endt, V. H. W., Milders, J., van der Willik, E. M., de Rooij, E. N. M., Dekkers, O. M., Rotmans, J. I., & van Diepen, M. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa160 · Cited by 123
Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic
Kyrou, I., Karteris, E., Robbins, T., Chatha, K. K., Drenos, F., & Randeva, H. S. (2020) · BMC Medicine · doi:10.1186/s12916-020-01697-5 · Cited by 123
Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients
Silverio, A., Maio, M. D., Citro, R., Esposito, L., Iuliano, G., Bellino, M., Baldi, C., Luca, G. D., Ciccarelli, M., Vecchione, C., et al. (2021) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01816-3 · Cited by 123
Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome
Lam, K. W., Chow, K. W., Vo, J. C., Hou, W., Li, H., Richman, P. S., Mallipattu, S. K., Skopicki, H. A., Singer, A. J., & Duong, T. Q. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa447 · Cited by 118
Self-citation
Mortality Predictive Value of APACHE II and SOFA Scores in COVID-19 Patients in the Intensive Care Unit
Beigmohammadi, M. T., Amoozadeh, L., Motlagh, F. R., Rahimi, M., Maghsoudloo, M., Jafarnejad, B., Eslami, B., Salehi, M. R., & Zendehdel, K. (2022) · Canadian Respiratory Journal · doi:10.1155/2022/5129314 · Cited by 119
Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease
Alnajjar, R. A., Mostafa, A., Kandeil, A., & Al-Karmalawy, A. A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05641 · Cited by 117
COVID-19 and diabetes: A bidirectional relationship
Lima-Martínez, M. M., Boada, C. C., Madera-Silva, M. D., Marín, W., & Contreras, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.004 · Cited by 117
COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system
Rysz, S., Al-Saadi, J., Sjöström, A., Farm, M., Campoccia Jalde, F., Plattén, M., Eriksson, H., Klein, M., Vargas-Paris, R., Nyrén, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22713-z · Cited by 111
Association of Renin-angiotensin-aldosterone System Inhibitors With Coronavirus Disease 2019 (COVID-19)- Related Outcomes in Korea: A Nationwide Population-based Cohort Study
Jung, S., Choi, J. C., You, S., & Kim, W. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa624 · Cited by 116
COVID‐19 and arterial hypertension: Hypothesis or evidence?
Tadić, M., Cuspidi, C., Grassi, G. M., & Mancia, G. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.13925 · Cited by 116
Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course
Bansal, R., Gubbi, S., & Muniyappa, R. (2020) · Endocrinology · doi:10.1210/endocr/bqaa112 · Cited by 119
Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2
Muchtaridi, M., Fauzi, M., Ikram, N. K. K., Gazzali, A. M., & Wahab, H. A. (2020) · Molecules · doi:10.3390/molecules25173980 · Cited by 113
Neutrophils in COVID-19: Not Innocent Bystanders
McKenna, E., Wubben, R., Isaza-Correa, J. M., Melo, A. M., Mhaonaigh, A. U., Conlon, N. P., O’Donnell, J. S., Cheallaigh, C. N., Hurley, T., Stevenson, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864387 · Cited by 117
Management of Heart Failure Patients with COVID-19: A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology
Zhang, Y., Coats, A. J. S., Zheng, Z., Adamo, M., Ambrosio, G., Anker, S. D., Butler, J., Xu, D., Mao, J., Khan, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1915 · Cited by 112
COVID-19: from epidemiology to treatment
Pericàs, J. M., Meneses, M. H., Sheahan, T. P., Quintana, E., Ambrosioni, J., Sandoval, E., Falces, C., Marcos, M. Á., Tuset, M., Vilella, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa462 · Cited by 110
COVID-19 in diabetic patients: Related risks and specifics of management
Orioli, L., Hermans, M. P., Thissen, J.-P., Maiter, D. M., Vandeleene, B., & Yombi, J. C. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.05.001 · Cited by 112

Authors: Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J.-J., Xie, J., Liu, Y.-M., Zhao, Y.-C., Huang, X., Lin, L., Xia, M., Chen, M.-M., Cheng, X., Zhang, X., Guo, D., Peng, Y., Ji, Y.-X., Chen, J., She, Z.-G., Wang, Y., Xu, Q., Tan, R., Wang, H., Lin, J., Luo, P., Fu, S., Cai, H., Ye, P., Xiao, B., Mao, W., Liu, L., Yan, Y., Liu, M., Chen, M., Zhang, X.-J., Wang, X., Touyz, R. M., Xia, J., Zhang, B.-H., Huang, X., Yuan, Y., Loomba, R., Liu, P. P., & Li, H.
Affiliations: Wuhan University (CN)
Central South University (CN)
Renmin Hospital of Wuhan University (CN)
Institute of Model Animal of Wuhan University (P.Z., L.Z., F.L., J.-J.Q., Y.-M.L., Y.-C.Z., X. Huang, L. Lin, M.X., M.-M.C., X.C., Y.-X.J., J. Chen, Z.-G.S., X.-J.Z., H.L.)
From the Cardiology (P.Z., L.Z., J.-J.Q., J. Xie, Y.-M.L., Y.-C.Z., X. Huang, M.-M.C., X.C., Z.-G.S., X.-J.Z., H.L.), Renmin Hospital of Wuhan University
Zhongnan Hospital of Wuhan University (CN)
University of California, Los Angeles (US)
Queen Mary University of London (GB)
Wuhan Kanghuashuhai Technology Company (R.T.), Wuhan
Wuhan Ninth Hospital (H.C., M.L.)
Central Hospital of Wuhan (CN)
Stomatology, Xiantao First People’s Hospital (B.X.)
Huanggang Central Hospital (CN)
Ezhou Central Hospital (CN)
Wuhan No. 7 Hospital (CN)
University of Glasgow (GB)
Huazhong University of Science and Technology (CN)
Neonatology (B.-H.Z.), Renmin Hospital of Wuhan University
University of California San Diego (US)
Ottawa Heart Institute (CA)
Corresponding author: Zhang, Peng
Zhu, Lihua
Cai, Jingjing
Lei, Fang
Qin, Juan-Juan
ORCID: Zhang, Peng
Zhu, Lihua
Cai, Jingjing
Lei, Fang
Qin, Juan-Juan
Xie, Jing
Huang, Xuewei
Lin, Lijin
Cheng, Xu
Zhang, Xiao
Guo, Deliang
Peng, Yuanyuan
Ji, Yan-Xiao
Chen, Jing
She, Zhi-Gang
Wang, Yibin
Xu, Qingbo
Wang, Haitao
Lin, Jun
Luo, Pengcheng
Fu, Shouzhi
Cai, Hongbin
Ye, Ping
Xiao, Bing
Liu, Mingyu
Chen, Manhua
Zhang, Xiao-Jing
Wang, Xinghuan
Touyz, Rhian M.
Xia, Jiahong
Huang, Xiaodong
Yuan, Yufeng
Loomba, Rohit
Liu, Peter P.
Li, Hongliang
Venue: Circulation Research
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2020-06-05
Volume: 126
Issue: 12
Pages: 1671-1681
ISSN: 0009-7330 (ISSN-L)
1524-4571
DOI: 10.1161/circresaha.120.317134
PMC: PMC7265882
OpenAlex: W3016572296
Cited by: 1,133
References: 32
Citations by year: 2026: 6 · 2025: 16 · 2024: 47 · 2023: 81 · 2022: 120 · 2021: 324 · 2020: 537
FWCI: 34.87
Type: journal article
Language: en
Update notices: correction (2020-08-27)
Open access: hybrid
doi.org
Licence: cc-by
Locations: Circulation Research (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: National Key R&D program of China (2016YFF0101504, 2020YFC0845500)
National Science Foundation of China (81630011; 81970364;81970070;81970011;81870171; 81700356)
Major Research Plan of the National Natural Science Foundation of China (91639304)
Hubei Science and Technology Support Project (2019BFC582; 2018BEC473; 2017BEC001)
Medical flight plan of Wuhan University
Topics: Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
Keywords: COVID-19 pandemic, hypertension, ACE inhibitors, angiotensin receptor blockers, all-cause mortality, antihypertensive drugs, hospitalized patients, SARS-CoV-2, 2020 outbreak, propensity score matching
MeSH terms: COVID-19, Aged, Angiotensin-Converting Enzyme Inhibitors, Female, Humans, Hypertension, Inpatients, Male, Middle Aged, Pneumonia, Viral, Hospital Mortality, Coronavirus Infections, Angiotensin Receptor Antagonists, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks